Company Fact Sheet

Corporate Facts

Life Technologies (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition.

Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better.

Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. The company had sales of more than $3.3 billion, employs approximately 9,000 people, has a presence in 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc.

Corporate Headquarters
5791 Van Allen Way
Carlsbad, California 92008
P: (760) 603-7200
F: (760) 602-6500
www.lifetechnologies.com
www.invitrogen.com
www.appliedbiosystems.com

Corporate Management

Gregory T. Lucier, Chairman and Chief Executive Officer
Mark Stevenson, President and Chief Operating Officer
David F. Hoffmeister, Chief Financial Officer
Nicolas Barthelemy, President, Cell Systems
Joe Beery, Chief Information Officer
Claude D. Benchimol, Ph.D., Senior Vice President, Research and Development, Genetic Systems
Bernd Brust, President and Chief Commercial Operations Officer
John Cottingham, Chief Legal Officer
Peter Dansky, President, Molecular Biology Systems
Paul Grossman, Ph.D., Senior Vice President, Strategy and Corporate Development
Peter Leddy, Ph.D., Senior Vice President, Global Human Resources
John “Kip” Miller, President, Genetic Systems
Mark O’Donnell, Senior Vice President, Global Operations and Services
Brian Pollok, Ph.D., Chief Scientific Officer, Head of Global Research and Development
Kelli A. Richard, Vice President, Finance and Chief Accounting Officer
Amanda Clardy, Chief Marketing Officer
Eileen Pattinson, Senior Director, Investor Relations
Farnaz Khadem, Senior Director, Corporate Communications and Public Relations

Click here for more information on our corporate management.

News

  • TGen Study

    LifeTechnologies Corporation announced that it is collaborating with the Translational Genomics Research Institute (TGen) and US Oncology to sequence the genomes of 14 patients afflicted with triple negative breast cancer whose tumors have progressed despite multiple other therapies. The goal of this first-of-its-kind research collaboration is to demonstrate whether genomic sequencing of cancer tissue can provide clues for treatment strategies for these individuals.

    Read All Close
  • SMS Technology

    Life Technologies Corporation announced early stage results from its single molecule sequencing (SMS) technology. The technology promises to combine virtually unlimited continuous long read lengths with unmatched accuracy to deliver targeted genomic sequence data in a matter of hours, paving the way for sequencing to become a commonplace tool in research laboratories and clinical settings worldwide.

    Read All Close
  • SOLiD PI ANNOUNCED

    Life Technologies Corporation today announced plans for the Applied Biosystems SOLiD(TM) PI System, a new highly accurate, flexible and easy-to-use genomic analysis platform that will bring next-generation sequencing within the grasp of all life science research laboratories worldwide. Early customer adoption of the SOLiD PI System is expected to begin in the second half of 2010.

    Read All Close

Life (Common Stock)